Sporet levering verden over | Forventet 9–14 hverdage

Din kurv

Din indkøbskurv er tom

Begynd at browse

Gratis fragt på ordrer over €500.

Subtotal€0
Gå til betaling
RestitutionTidlig klinisk

TB-500

Publiceret forskning og dokumentationsgrundlag

Thymosin beta-4 (Tb4) is a 43-amino-acid endogenous actin-sequestering peptide with a large preclinical literature on tissue repair, angiogenesis, anti-fibrotic activity and inflammation resolution. TB-500 is the synthetic Ac-LKKTETQ fragment marketed as a Tb4 analogue; almost all published biology concerns full-length Tb4 rather than the fragment, and the two are frequently conflated. Human evidence is more developed than for most peptides in this category, including completed phase 1 safety studies, a phase 2 dry eye trial and a 2025 study reporting outcomes in both mice and STEMI patients, but no product is approved for musculoskeletal recovery.

Kort fortalt
  • Thymosin beta-4 er et peptid med 43 aminosyrer; TB-500 er et syntetisk fragment.
  • Studier rapporterede effekter på vævsreparation og angiogenese i dyr og celler.
  • Ingen humane forsøg har testet det til sene-, ledbånd- eller muskelskader.

24 studier · 10 siden 2023 · nyeste 2026

Undersøgelser citeret
24
Publiceret 2023+
10
Nyeste artikel
2026
Sidst gennemgået
okt. 2026

Tilbagevendende temaer i litteraturen

  • actin sequestration and cell migration
  • angiogenesis and endothelial migration
  • cardiac repair and epicardial activation
  • anti-fibrotic activity
  • corneal and dermal wound healing
  • inflammation resolution
  • TB-500 fragment pharmacology and doping detection

Stofidentifikatorer

CAS
885340-08-9
PubChem
62707662

Regulatorisk status

Anbefalet af et FDA-rådgivende udvalg.

Den 23–24 July 2026 overvejede FDA's Pharmacy Compounding Advisory Committee TB-500 til 503A Bulks List og anbefalede dets tilføjelse ved en rapporteret afstemning på 8–6 with one abstention. Heard as TB-500 free base and TB-500 acetate, and recommended on a divided vote.

Dette er ikke en godkendelse. Udvalget rådgiver; det beslutter ikke. Anbefalingen er ikke bindende, FDA har ikke afsluttet regeludformningen, der formelt ville ændre noget, og inkludering på 503A Bulks List svarer ikke til FDA-godkendelse af et lægemiddel. Listen regulerer også apotekssammensætning til patienter, hvilket er en separat aktivitet fra levering kun til forskningsbrug.

Hvad den rådgivende afstemning i juli 2026 faktisk gjorde redegør for processen, de andre stoffer der blev hørt, og de fire ting afstemningen rutinemæssigt fejlrapporteres som betydende.

Kemisk identitet

Hvad TB-500 er, kemisk.

Molekylformel
C38H68N10O14
Molekylvægt
889.0 g/mol
CAS-nummer
885340-08-9
PubChem CID
62707662
Også skrevet som

TB500

Disse tal stammer fra PubChem-posten for denne forbindelse og beskriver den frie base. Lyofiliseret peptid leveres normalt som et acetat- eller trifluoroacetatsalt og indeholder restvand, så massen af pulver i et hætteglas er ikke den samme mængde, som molekylvægten ovenfor ville antyde. Kromatografisk renhed på et analysecertifikat løser heller ikke den forskel — Sådan læses et analysecertifikat forklarer hvorfor.

Evidensen

24 offentliggjorte studier.

Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.

  1. 01Systematisk gennemgang2025

    Medical and surgical interventions for neurotrophic keratopathy.

    Kruoch Z, et al. · Cochrane Database Syst Rev · Cochrane systematic review and meta-analysis, 7 RCTs, 494 participants

    For 0.1% RGN-259, one trial (18 participants) gave a risk ratio of 9.00 (95% CI 0.57 to 141.88) for corneal re-epithelialisation, rated low-certainty evidence; overall evidence for neurotrophic keratopathy treatments was low to very low certainty. The RGN-259 trial in this review used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  2. 02Humant klinisk2025

    Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion

    Zhang Y, et al. · Cardiovasc Res · murine myocardial ischemia/reperfusion models plus subjects with acute ST-segment elevation myocardial infarction after primary percutaneous coronary intervention

    Recombinant human thymosin beta 4 was evaluated for its effect on chronic cardiac functional recovery after ischemia/reperfusion in mice and in STEMI patients following reperfusion. This is the most substantial human cardiac dataset for the peptide to date. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  3. 03Humant klinisk2022

    0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.

    Sosne G, et al. · Int J Mol Sci · phase 3 double-masked placebo-controlled RCT, neurotrophic keratopathy stage 2-3, n=18

    Complete healing at 4 weeks occurred in 6/10 RGN-259 (topical thymosin beta-4) vs 1/8 placebo patients (p=0.066); healing was significant at day 43 with no recurrences, ocular discomfort improved, and no significant adverse effects were observed. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  4. 04Humant klinisk2021

    A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers

    Wang X, et al. · J Cell Mol Med · phase 1 randomised double-blind study; 54 healthy subjects across 7 single-dose cohorts (0.05 to 25.0 ug/kg intravenous) and 30 subjects in 3 multiple-dose cohorts

    The trial evaluated safety, tolerability, pharmacokinetics and anti-drug antibody formation for recombinant human Tb4 (NL005) after single and multiple intravenous doses in healthy volunteers. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  5. 05Humant klinisk2021

    Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.

    Yu R, et al. · Microb Biotechnol · comparative clinical study, n=71 patients with scalp seborrheic dermatitis given recombinant human thymosin beta-4 (rhTβ4) gel or ketoconazole lotion for 4 weeks, with 21 healthy individuals as a microbiome reference group

    The rhTβ4 gel gave significantly greater and more sustained improvement than ketoconazole in scalp flaking and erythema scores and in skin physiology measures, and shifted the scalp microbiome towards that of healthy individuals. The abstract does not say how patients were allocated and does not report adverse events. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  6. 06Humant klinisk2021

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.

    Lee E, Padgett B · Altern Ther Health Med · retrospective single-clinic chart review 2019-2020, 17 patients with knee pain given intra-articular BPC 157 alone or combined with thymosin beta-4 (TB4); 4 of the 16 reached by telephone had received both peptides

    Of the 4 patients given BPC 157 plus TB4, 75% reported significant improvement in knee pain and 25% had no relief. Pain was self-rated by telephone without validated instruments or a control group. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  7. 07Humant klinisk2015

    Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

    Sosne G, et al. · Cornea · multicentre, randomised, double-masked, placebo-controlled 56-day phase 2 trial at 2 US sites; 9 patients with severe dry eye, RGN-259 0.1% or vehicle 6 times daily for 28 days with 28-day follow-up

    Tb4 eye drops improved signs and symptoms of severe dry eye compared with vehicle in this small phase 2 trial, which included patients with graft-versus-host-associated disease. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  8. 08Humant klinisk2015

    Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.

    Sosne G, Ousler GW · Clin Ophthalmol · single-centre randomised double-masked placebo-controlled phase 2 trial, n=72 subjects with moderate to severe dry eye, thymosin beta-4 eye drops (RGN-259) or placebo for 28 days, tested in a controlled adverse environment (CAE) chamber

    Neither primary endpoint (ocular discomfort and inferior corneal staining on day 29) differed significantly from placebo, but discomfort scores in the controlled environment on day 28 were 27% lower with thymosin beta-4 (P=0.0244) and central and superior corneal staining improved significantly; no adverse events were observed. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  9. 09Humant klinisk2010

    A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers

    Ruff D, et al. · Ann N Y Acad Sci · 4 cohorts of 10 healthy subjects; single intravenous placebo or synthetic Tb4 at 42, 140, 420 or 1260 mg, then the same dose daily for 14 days

    Adverse events were infrequent and mild across the ascending single and 14-day repeat intravenous dose ranges, with pharmacokinetic parameters characterised. This remains the primary human safety dataset for systemic Tb4. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  10. 10Humant klinisk2010

    The effect of thymosin treatment of venous ulcers

    Guarnera G, et al. · Ann N Y Acad Sci · multicentre randomised controlled phase 2 study of topical synthetic Tb4 in patients with chronic venous ulcers of the lower limbs

    The trial assessed safety, tolerability and healing effect of topical Tb4 added to standard care in venous leg ulcers. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

  11. 11Humant klinisk2010

    Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.

    Dunn SP, et al. · Ann N Y Acad Sci · compassionate-use case series, nine patients aged 37-84 with chronic nonhealing neurotrophic corneal epithelial defects, thymosin beta-4 eye drops for 28 or 49 days with 30 days of follow-up

    The six patients with geographic defects showed marked healing without clinically significant neovascularisation, while the three with punctate defects showed no demonstrable change; stromal thinning was seen in one patient. All patients reported reduced ocular irritation soon after starting treatment. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).

    Rapporteret sikkerhedsfund. Stromal thinning was observed in one patient.

  12. 12Dyr in vivo2026

    Recombinant human Thymosin beta4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling

    Zhao TR, et al. · Mol Biomed · murine experimental colitis and intestinal fibrosis models, with TMSB4X expression profiling in colonic tissue from inflammatory bowel disease patients

    TMSB4X, the gene encoding Tb4, was downregulated in colonic tissue from IBD patients, and recombinant human Tb4 reduced colitis severity and intestinal fibrosis in mice via suppression of mineralocorticoid receptor signalling.

  13. 13Dyr in vivo2026

    Thymosin beta4 alleviates sepsis-associated acute kidney injury by suppressing MAPK signaling pathway

    Ouyang X, et al. · Clin Sci (Lond) · in vivo and in vitro lipopolysaccharide-induced models of sepsis-associated acute kidney injury; Tb4 given 30 minutes after LPS exposure

    Tb4 administration after LPS exposure attenuated markers of sepsis-associated acute kidney injury, with the protective effect linked to suppression of MAPK signalling.

  14. 14Dyr in vivo2026

    Reparative Outcomes in Corneal Infection: Linking Adjunctive Tbeta4 Treatment to Nerve Regeneration and Visual Function

    Ebrahim AS, et al. · Invest Ophthalmol Vis Sci · bacterial keratitis induced in C57BL/6 mice by inoculating wounded corneas; adjunctive Tb4 with ciprofloxacin

    The study evaluated whether adjunctive Tb4 supports corneal nerve regeneration and restores visual function after infection, extending earlier findings that the combination reduces keratitis severity and enhances wound repair.

  15. 15Dyr in vivo2026

    Decidualization-empowered ECM hydrogel integrating sustained Tbeta4 release drives endometrial regeneration in intrauterine adhesions

    Liang Y, et al. · Nat Commun · murine intrauterine adhesion model treated with a decidualized-endometrium extracellular matrix hydrogel providing sustained Tb4 release

    A single application of the Tb4-releasing hydrogel shifted the uterine injury response away from fibrotic scarring and toward endometrial regeneration in mice.

  16. 16Dyr in vivo2025

    Tbeta4-Engineered ADSC Extracellular Vesicles Rescue Cell Senescence Through Separable Microneedle Patches for Diabetic Wound Healing

    Ding Y, et al. · Adv Sci (Weinh) · separable microneedle patches loaded with extracellular vesicles from Tb4-overexpressing adipose-derived stem cells, applied to aged diabetic wound models

    Tb4-modified extracellular vesicles delivered by microneedle patch reversed markers of cellular senescence and improved healing in chronic diabetic wounds aggravated by senescence.

  17. 17Dyr in vivo2025

    Inhaled exogenous thymosin beta 4 suppresses bleomycin-induced pulmonary fibrosis in mice via TGF-beta1 signalling pathway

    Yu R, et al. · J Pharm Pharmacol · bleomycin-induced pulmonary fibrosis in mice; nebulised recombinant human Tb4 given under three dosing strategies

    Nebulised recombinant human Tb4 suppressed bleomycin-induced pulmonary fibrosis in mice, with the anti-fibrotic effect associated with TGF-beta1 signalling.

  18. 18Dyr in vivo2013

    Thymosin beta4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing

    Evans MA, et al. · Nat Commun · zebrafish wounding model and mammalian cardiac injury

    Thymosin beta4-sulfoxide was identified downstream of wound-derived hydrogen peroxide as a resolution signal that depletes inflammatory macrophages and promotes cardiac wound healing. This established an inflammation-resolution mechanism distinct from actin binding.

  19. 19Dyr in vivo2013

    Thymosin β4 enhances the healing of medial collateral ligament injury in rat.

    Xu B, et al. · Regul Pept · rat medial collateral ligament transection model, 4 weeks

    Local thymosin beta-4 in fibrin sealant produced more organised collagen fibre bundles, larger collagen fibril diameters and better biomechanical properties of the healing ligament than control.

  20. 20Dyr in vivo2011

    De novo cardiomyocytes from within the activated adult heart after injury

    Smart N, et al. · Nature · adult mouse heart, epicardial progenitor population primed with thymosin beta4 prior to myocardial infarction

    Priming with thymosin beta4 mobilised a resident adult epicardial progenitor population that contributed structurally and functionally to new myocardium after infarction. This is the landmark cardiac-regeneration result for the peptide.

  21. 21Dyr in vivo2004

    Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.

    Bock-Marquette I, et al. · Nature · mouse coronary artery ligation model plus embryonic/postnatal cardiomyocytes

    Thymosin beta-4 formed a complex with PINCH and integrin-linked kinase, activating Akt; after coronary ligation it increased ILK/Akt activity, enhanced early cardiomyocyte survival and improved cardiac function.

  22. 22Dyr in vivo1999

    Thymosin beta4 accelerates wound healing

    Malinda KM, et al. · J Invest Dermatol · rat full-thickness dermal wound model; topical or intraperitoneal Tb4

    Tb4 increased re-epithelialisation by 42 percent at 4 days and up to 61 percent at 7 days versus saline controls, with at least 11 percent greater wound contraction by day 7 and increased collagen deposition and angiogenesis. This is the foundational wound-healing paper.

  23. 23In vitro2024

    Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro

    Rahaman KA, et al. · J Chromatogr B Analyt Technol Biomed Life Sci · in vitro metabolic incubations and rat administration, with synthesised authentic standards; scratch wound healing assays for the metabolites

    This is one of the few papers addressing TB-500 (Ac-LKKTETQ) itself rather than full-length Tb4. It established simultaneous quantification of TB-500 and its metabolites and screened them for wound healing activity in vitro.

  24. 24In vitro2023

    TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs.

    Delcourt V, et al. · Drug Test Anal · analytical (mass-spectrometric) examination of TB500, TB1000 and SGF1000 products sold online

    The content of products sold as TB500/TB1000 was not consistently matched to their described composition, and SGF1000 consisted mainly of sheep extracellular matrix and blood proteins.

    Rapporteret sikkerhedsfund. Online TB-500 products did not consistently contain the stated peptide, indicating misbranding and adulteration.

Begrænsninger

Hvad denne evidens ikke fastslår.

No human trial has tested Tb4 or TB-500 for tendon, ligament or muscle injury, which is the marketed use; the completed human trials cover dry eye, venous ulcers, cardiac ischemia and healthy-volunteer safety. The specific TB-500 fragment (Ac-LKKTETQ) has almost no independent pharmacology of its own, and its equivalence to full-length Tb4 is assumed rather than demonstrated. Tb4 is also prohibited in sport and in equine competition, and several of the recent papers are doping-detection methods rather than efficacy studies.

Almindelige spørgsmål om forskningen.

What is TB-500?

TB-500 is the research designation for synthetic thymosin beta-4 chemistry supplied for laboratory work. Thymosin beta-4 is a naturally occurring 43-amino-acid peptide and the main actin-sequestering molecule in mammalian cells; it is studied for its role in cell migration, angiogenesis, and tissue repair.

How does TB-500 differ from BPC-157?

They are unrelated molecules studied in overlapping models. TB-500 derives from thymosin beta-4 and is investigated for actin regulation, cell migration, and angiogenesis; BPC-157 is a gastric-juice-derived pentadecapeptide studied in tendon, ligament, and gastrointestinal models. The two are frequently co-studied, which is why combined vials are offered.

Why do some papers describe a short fragment instead?

Much of the activity attributed to thymosin beta-4 maps to its central actin-binding motif (LKKTETQ), so some studies work with the full 43-amino-acid peptide and others with shorter fragments. Comparing protocols across papers requires checking which preparation was used.

Fås i vores katalog

Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.